| 主权项 |
1. A method for identifying whether a subject is more or less likely to be responsive to VEGF-based therapy, comprising screening a nucleic acid sample obtained from the subject to provide output information which identifies the presence or absence of an allelic variant, wherein the allelic variant is selected from the group consisting of:
i. rs6921438 ii. rs4416670 iii. rs6993770 iv. rs10738760 wherein the presence or absence of an allelic variant indicates whether the subject is more or less likely to be responsive to VEGF-based therapy, wherein if the nucleic acid sample is screened for the allelic variant rs6921438, a guanine residue at base 323 of SEQ ID No.1 at one or both alleles indicates that the subject is more likely to be responsive to VEGF-based therapy, wherein if the nucleic acid sample is screened for the allelic variant rs4416670, a thymine residue at base 221 of SEQ ID No.2 at one or both alleles indicates that the subject is more likely to be responsive to VEGF-based therapy, wherein if the nucleic acid sample is screened for the allelic variant rs6993770, a thymine residue at base 235 of SEQ ID No.3 at one or both alleles indicates that the subject is less likely to be responsive to VEGF-based therapy, and/or wherein if the nucleic acid sample is screened for the allelic variant rs10738760, a guanine residue at base 201 of SEQ ID No.4 at one or both alleles indicates that the subject is more likely to be responsive to VEGF-based therapy. |
